It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite the high prevalence of both cervico-vaginal human papillomavirus (HPV) infection and bacterial vaginosis (BV) worldwide, their causal relationship remains unclear. While BV has been presumed to be a risk factor for HPV acquisition and related carcinogenesis for a long time, here, supported by both a large retrospective follow-up study (n = 6,085) and extensive in vivo data using the K14-HPV16 transgenic mouse model, we report a novel blueprint in which the opposite association also exists. Mechanistically, by interacting with several core members (NEMO, CK1 and β-TrCP) of both NF-κB and Wnt/β-catenin signaling pathways, we show that HPV E7 oncoprotein greatly inhibits host defense peptide expression. Physiologically secreted by the squamous mucosa lining the lower female genital tract, we demonstrate that some of these latter are fundamental factors governing host-microbial interactions. More specifically, several innate molecules down-regulated in case of HPV infection are hydrolyzed, internalized and used by the predominant Lactobacillus species as amino acid source sustaining their growth/survival. Collectively, this study reveals a new viral immune evasion strategy which, by its persistent/negative impact on lactic acid bacteria, ultimately causes the dysbiosis of vaginal microbiota.
Here, the authors show that HPV infection leads to downregulation of host mucosal innate peptides, which are in turn used by predominant Lactobacillus species as amino acid source, promoting ultimately an imbalance in the vaginal flora.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Hervouet, Eric 2
; Cobraiville Gael 3 ; Taminiau Bernard 4
; Masson Murielle 5
; Gallego, Carmen 6 ; Mazzucchelli, Gabriel 7 ; Smargiasso Nicolas 7 ; Fleron Maximilien 8 ; Baiwir Dominique 8
; Hendrick Elodie 1 ; Pilard Charlotte 1 ; Lerho, Thomas 1 ; Reynders Celia 1 ; Ancion, Marie 1 ; Greimers Roland 9 ; Twizere Jean-Claude 10
; Daube Georges 4
; Schlecht-Louf Geraldine 6
; Bachelerie Françoise 6 ; Jean-Damien, Combes 11 ; Melin Pierrette 12
; Fillet Marianne 3 ; Delvenne Philippe 13 ; Hubert, Pascale 1 ; Herfs, Michael 1
1 University of Liege, Laboratory of Experimental Pathology, GIGA-Cancer, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
2 University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615); University of Bourgogne Franche-Comté, EPIGENEXP platform, Besançon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615)
3 University of Liege, Laboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
4 University of Liege, Department of Food Sciences-Microbiology, Fundamental and Applied Research for Animals and Health (FARAH), Faculty of Veterinary Medicine, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
5 University of Strasbourg, Ecole Supérieure de Biotechnologie Strasbourg, UMR 7242, CNRS, Illkirch, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291)
6 University of Paris-Saclay, INSERM UMR 996, Inflammation Microbiome and Immunosurveillance, Clamart, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
7 University of Liege, Laboratory of Mass Spectrometry, Department of Chemistry, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
8 University of Liege, Laboratory of Mass Spectrometry, Department of Chemistry, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253); University of Liege, GIGA Proteomic Facility, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
9 University Hospital Center of Liege, Department of Pathology, Liege, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858)
10 University of Liege, Laboratory of Signaling and Protein Interactions, GIGA-Molecular Biology of Diseases, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
11 International Agency for Research on Cancer, World Health Organization, Infections and Cancer Epidemiology Group, Lyon, France (GRID:grid.17703.32) (ISNI:0000000405980095)
12 University Hospital Center of Liege, Department of Clinical Microbiology, Liege, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858)
13 University of Liege, Laboratory of Experimental Pathology, GIGA-Cancer, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253); University Hospital Center of Liege, Department of Pathology, Liege, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858)




